Wells Fargo & Company In8 Bio, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.95 - $1.69 $84 - $150	89 Added 56.33%	247 $0
Q4 2023 Feb 09, 2024	SELL	$0.69 - $2.34 $6,942 - $23,542	-10,061 Reduced 98.45%	158 $0
Q3 2023 Nov 13, 2023	BUY	$0.92 - $1.74 $47 - $90	52 Added 0.51%	10,219 $10,000
Q2 2023 Aug 15, 2023	BUY	$1.05 - $3.24 $43 - $132	41 Added 0.4%	10,167 $15,000
Q1 2023 May 12, 2023	BUY	$1.17 - $2.83 $2 - $5	2 Added 0.02%	10,126 $13,000
Q4 2022 Feb 13, 2023	BUY	$1.39 - $2.47 $13,990 - $24,860	10,065 Added 17059.32%	10,124 $23,000
Q3 2022 Nov 14, 2022	BUY	$1.77 - $2.89 $58 - $95	33 Added 126.92%	59 $0
Q2 2022 Aug 12, 2022	BUY	$2.02 - $4.68 $4 - $9	2 Added 8.33%	26 $0
Q3 2021 Nov 15, 2021	BUY	$6.71 - $10.0 $161 - $240	24 New	24 $0

7.62M

Ticker INAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,502,200
Market Cap $6.13M
Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.